Table 3: Comparison of epidemiological, clinical and treatment data in psoriatic arthritis patients with and without depression and correlation of depression with quality of life, age, disease duration and activity indexes.

COMPARISON STUDIES

 

With depression

n = 28 (51.8%)

Without depression

n = 26 (48.1%)

P

Females/Males

15/13

12/14

0.58

Tobacco exposure

15 (53.3%)

13

0.79

Polyarthritis

10 (35.7%)

4 (15.3%)

0.42

Oligoarthritis

14 (50%)

16 (61.5%)

Axial

12 (42.8%)

12 (46.1%)

Distal interphalangeal

2 (7.1%)

3 (11.5%)

Treatment

DMARDs (Methotrexate + leflunomide)

18 (64.2%)

16 (61.5%)

0.83

Anti-TNF-alpha

9 (32.1%)

9 (34.6%)

0.84

CORRELATION STUDIES OF CES-D QUESTIONNAIRE RESULTS

 

Rho

95% Confidence interval

P

Age

0.18

-0.09 to 0.43

0.18

Arthritis duration

-0.008

-0.28 to +0.27

0.95

Psoriasis duration

-0.004

-0.32 to +0.23

0.73

PASI

0.50

+0.27 to +0.68

< 0.0001

ASDAS -ESR

0.26

-0.01 to +0.50

0.057

ASDAS-CRP

0.17

-0.10 to +0.43

0.20

CRP

-0.04

-0.32 to +0.23

0.73

ESR

0,14

-0.14 to 0.40

0.31

SF-12 (physical domain)

-0.55

-0.71 TO -0.32

< 0.0001

SF-12 (mental domain)

-0.80

-0.88 to -0.68

< 0.0001

DMARDs: Disease Modifying Rheumatic Drugs; PASI: Psoriasis Area Severity Index; ASDAS: Ankylosing Spondylitis Disease Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; SF-12: Short Form health survey with 12 questions; CES-D: Center for Epidemiologic Studies Depression scale